- Currently Available in Canada -
TORONTO, Oct. 31, 2019 /CNW/ - Teva Canada Limited, a
subsidiary of Teva Pharmaceutical Industries Ltd., announced the
launch of PrTeva-Fingolimod 0.5 mg capsules, a
Health Canada approved, bioequivalent generic version of
PrGilenya® (fingolimod hydrochloride) in
Canada.
PrTeva-Fingolimod (fingolimod
hydrochloride) is indicated as monotherapy for the treatment of
patients with the relapsing-remitting form of multiple sclerosis
(MS) to reduce the frequency of clinical exacerbations and to
delay the progression of physical disability.
PrTeva-Fingolimod is generally recommended in MS
patients who have had an inadequate response to, or are unable to
tolerate, one or more therapies for multiple sclerosis.
"MS is known as 'Canada's disease' as our country has the
highest prevalence in the world,i with over
77,000 Canadians currently living with this chronic neurological
conditionii," said Christine
Poulin, Senior Vice President and General Manager,
Teva Canada. "With the launch of
PrTeva-Fingolimod, we are pleased to offer
patients a cost-effective, bioequivalent treatment option to
PrGilenya® and, through the
Teva-Fingolimod Patient Care ProgramSM,
individualized support and a seamless transition process from brand
to generic."
Teva-Fingolimod Patient Care
ProgramSM
The Teva-Fingolimod Patient Care ProgramSM is
designed to support the patient journey for those taking
PrTeva-Fingolimod. It will support
patients who are moving from the brand
(PrGilenya®) medication to Teva Canada's bioequivalent generic version
(PrTeva-Fingolimod) and new patients who are
starting fingolimod hydrochloride treatment for the first time.
Elements of the program include:
- Patient Enrolment: Completed by the prescriber, pharmacy
team or patient directly (enrolment form available here:
www.TevaCanada.com/Fingolimod-Support)
- First Dose Monitoring: Appointment coordination
(required for new patients only, starting fingolimod hydrochloride
treatment for the first time)
- Financial Support: Trained Patient Care Specialists will
help investigate coverage options and provide reimbursement
navigation and co-pay support to enroled patients.
For additional information on this program, call 1-855-868-7622
or visit: www.TevaCanada.com/Fingolimod-Support
Fingolimod hydrochloride (brand:
PrGilenya®) had annual sales of approximately
$103 million in Canada, based on IQVIA sales data as of
August 2019.
PrTeva-Fingolimod is available immediately to
pharmacies across Canada. The launch of
PrTeva-Fingolimod demonstrates Teva Canada's research and development
capabilities and desire to continue to provide patients with a
range of treatment options and resources.
About Multiple Sclerosis
MS is currently classified as an autoimmune disease of the
central nervous system (brain, spinal cord). The disease attacks
myelin, the protective covering of the nerves, causing inflammation
and often damaging the myelin. Myelin is necessary for the
transmission of nerve impulses through nerve fibres. MS is
unpredictable and can cause symptoms such as extreme fatigue, lack
of coordination, weakness, tingling, impaired sensation, vision
problems, bladder problems, cognitive impairment and mood changes.
Its effects can be physical, emotional and financial.iii
It affects three times as many women as men and strikes people in
the prime of their lives, as the average age of onset is
31.iv Canada has one of the highest rates of
multiple sclerosis (MS) in the world, with an average of 8 women
and 3 men diagnosed with MS every day.v
MS is divided into several basic categories, depending on the
pattern of the individual's disease. Relapsing remitting MS
is a category characterized by unpredictable but clearly defined
periods during which symptoms are apparent. These ''relapses" are
also known as episodes, attacks, exacerbations, or flare-ups.
Relapses can last for varying periods (from a few days to several
months) and are followed by periods of recovery, or 'remission'
during which many functions return. About 85% of people are
diagnosed with this form of MS.vi
Helping People Live Better Days
At Teva, we care deeply about the wellbeing of the patients,
caregivers and communities who rely on us. We serve 200 million
people every day, with a promise to help them take better control
of their health. From our role as a global leader in generic and
brand-name medicines to the innovative solutions we create for our
healthcare partners, we offer a unique perspective on health—here
in Canada and around the
world.
About Teva Canada Limited
Teva Canada Limited, headquartered in Toronto, has provided affordable healthcare
solutions for over 50 years, with sales of more than $1 billion in 2018 and nearly 225,000
prescriptions filled with our products every dayvii.
Originally Novopharm Limited, Teva Canada Limited specializes in
the development, production and marketing of high-quality generic
prescription pharmaceuticals and through our branded division, Teva
Canada Innovation, focuses on a diverse line of innovative products
in a variety of therapeutic areas. Teva
Canada employs more than 1,000 professionals, markets over
385viii products in 1,000 SKUs in Canada and is a subsidiary of Teva
Pharmaceutical Industries Ltd., the world's largest generic drug
maker. For more information, visit: www.tevacanada.com
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has
been developing and producing medicines to improve people's lives
for more than a century. We are a global leader in generic and
specialty medicines with a portfolio consisting of over 35,000
products in nearly every therapeutic area. Around 200 million
people around the world take a Teva medicine every day, and are
served by one of the largest and most complex supply chains in the
pharmaceutical industry. Along with our established presence in
generics, we have significant innovative research and operations
supporting our growing portfolio of specialty and biopharmaceutical
products. Learn more at http://www.tevapharm.com
_______________________________________
|
i
|
Source: St. Michael's
Hospital – Newsroom – "St. Michael's Hospital announces plans to
create world's leading treatment and research centre for multiple
sclerosis, "Canada's disease"
|http://www.stmichaelshospital.com/media/detail.php?source=hospital_news/2017/1122 -
Accessed September 2019
|
ii
|
Source: Government of
Canada – Health - Publications – Diseases and conditions – Diseases
- Multiple Sclerosis in Canada |
https://www.canada.ca/en/public-health/services/chronic-diseases/multiple-sclerosis.html -
Accessed September 2019
|
iii
|
Source: MS Society of
Canada – About MS – What is MS? |
https://mssociety.ca/about-ms/what-is-ms - Accessed September
2019
|
iv
|
Source: St. Michael's
Hospital – Newsroom – "St. Michael's Hospital announces plans to
create world's leading treatment and research centre for multiple
sclerosis, "Canada's disease" |
http://www.stmichaelshospital.com/media/detail.php?source=hospital_news/2017/1122 -
Accessed September 2019
|
v
|
Source: Government of
Canada – Health - Publications – Diseases and conditions – Diseases
- Multiple Sclerosis in Canada
|https://www.canada.ca/en/public-health/services/publications/diseases-conditions/multiple-sclerosis-infographic.html -
Accessed September 2019
|
vi
|
Source: MS Society of
Canada – About MS – What is MS? - Does everyone experience MS the
same way? | https://mssociety.ca/about-ms/what-is-ms -
Accessed September 2019
|
vii
|
Source: IQVIA CDH
& Compuscript MAT July 2019
|
viii
|
Source: IQVIA CDH
& Compuscript MAT July 2019
|
SOURCE Teva Canada Limited